BJH - volume 9, issue 5, september 2018
C. Bonnet MD, PhD, M.C. Ngirabacu , M. Maerevoet MD, V. De Wilde MD, PhD, E. Van den Neste MD, PhD, M. André MD
The 4th edition of the LYSA meeting was organised by Professor Steven Legouill’s team and held in Nantes from the 8th to 10th February, 2018. It was a real opportunity for the 500 participants to learn novelties on lymphoma and to be updated on ongoing clinical trials conducted by this cooperative group. All the presentations were outstanding and gave us new indications on how to better treat our patients in the near future.
(BELG J HEMATOL 2017;9(5):195–8)
Read moreBJH - volume 9, issue 5, september 2018
T. Feys MBA, MSc
From the 20th till the 24th of May 2018, Glasgow formed the background for the annual meeting of the World Federation of Hemophilia (WFH), the largest international meeting for the bleeding disorders community. The therapeutic options for people with haemophilia (PWH) have rapidly evolved in the last five years. Moving on from conventional plasma-derived and recombinant clotting concentrates (CFC), there are now extended half-life CFCs as well as several novel haemostasis agents (e.g. emicizumab). In addition, gene transfer proved to be successful for both haemophilia A and B patients. It has been demonstrated that all these products provide better haemostasis and convenience than conventional CFCs. This summary will focus on new data presented with some of these novel therapeutic options during WFH 2018. For a complete overview of abstracts presented during the meeting we would like to refer to the official congress website (https://www.wfh.org/congress/en/home).
(BELG J HEMATOL 2017;9(5):199–201)
Read moreBJH - volume 4, issue 3, september 2013
A. Ferster MD, PhD, B. Gulbis MD, PhD
During the twelfth meeting dedicated to sickle cell disease and hereditary red cell disorders held in Brussels on 21 February 2013, several topics related to major aspects for the management of sickle cell disease were presented. Six of them are summarised.
(BELG J HEMATOL 2013;4(3): 115–116)
Read moreBJH - volume 4, issue 2, june 2013
A. Kornreich MD, A. Gothot MD, PhD
For the first time, during the course of its general annual meeting, the BHS hosted a satellite meeting organized by the Belgian Society for Analytical Cytology (BVAC/ABCA) to bring together clinicians with laboratory scientists and staff. The BVAC/ABCA program included state-of-the-art lectures, followed by a session focused on advances in genetic testing of haematological malignancies and finally a satellite symposium sponsored by Alexion on the deficiencies of complement regulators leading to thrombotic micro-angiopathies (TMA). All these presentations are available on the BVAC/ABCA website: http://www.cytometry.be/Gent2013.html
(BELG J HEMATOL 2013;4(2):77–82)
Read moreBJH - volume 4, issue 1, march 2013
T. Feys MBA, MSc
From the 8th till the 11th of December 2012, Atlanta, Georgia formed the background for the 54th annual meeting of the American Society of Hematology (ASH). With more than 20,000 attendees from 108 countries, the ASH annual meeting again proved to be without question the premier hematology meeting in the world. This report does not aim to summarise the entire meeting, but simply lists the key messages from this years’ meeting. For more elaborate information on the meeting, and a complete overview of the presented abstracts we would like to refer to the ASH website, www.hematology.org.
(BELG J HEMATOL 2013;1:39–42)
Read moreBJH - volume 3, issue 3, september 2012
T. Lodewyck MD
From April 1 till 4 2012, the 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held in Geneva. The feld of stem cell transplantation keeps on growing, with more than 30,000 transplants being reported to the EBMT in 2010. Some of the highlights of this meeting are briefly summarised.
(BELG J HEMATOL 2012;3:109–111)
Read moreBJH - volume 3, issue 3, september 2012
A. Bosly MD, PhD
The six best abstracts submitted at the European Hematology Association (EHA), 17th Meeting, 2012, Amsterdam were selected for the presidential symposium. Two of them were related to the whole exome analysis: one in T-acute lymphoblastic leukaemia (T-ALL) and one in multiple myeloma (MM).
(BELG J HEMATOL 2012;3:112–113)
Read more
Top
